Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZLI 14-day versus 28-day eradication therapy for new-onset Pseudomonas aeruginosa in pediatric cystic fibrosis
NL-OMON50497Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2018
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) and Pseudomonas aeruginosa airway infection comparing AZLI 28 days with AZLI 14 days followed by placebo 14 days (2 arms). Primary endpoint: Pseudomonas aeruginosa eradication over 28-day post-treatment follow-up. Started Nov 2018; status: completed.
02
Drugs
aztreonam
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa airway infection
Beyond the preview
Go deeper on NL-OMON50497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50497.